Quarterly report pursuant to Section 13 or 15(d)

Segments (Details)

v3.7.0.1
Segments (Details) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue $ 0 $ 8,800  
Lymphoseek license revenue 0 254,050  
Grant and other revenue 580,030 685,635  
Total revenue 580,030 948,485  
Cost of goods sold, excluding depreciation and amortization 0 1,489  
Research and development expenses, excluding depreciation and amortization 705,274 2,072,271  
Selling, general and administrative expenses, excluding depreciation and amortization 3,022,434 2,633,126  
Depreciation and amortization 76,790 74,966  
Income (loss) from operations (3,147,678) (3,758,401)  
Other expense (1,171,109) 1,088,824  
Equity in loss of R-NAV, LLC 0 (12,239)  
Income tax (expense) benefit 1,454,172 0  
Net income (loss) from continuing operations (2,864,615) (2,681,816)  
Loss from discontinued operations, net of tax (255,861) (1,004,433)  
Gain on sale of discontinued operations, net of tax 88,701,501 0  
Net income (loss) 85,581,025 (3,686,249)  
Total assets, net of depreciation and amortization 32,925,587   $ 12,461,676
Payments to Acquire Property, Plant, and Equipment 0 1,847  
UNITED STATES      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization 32,809,415 11,901,094  
Non Us [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 8,800  
Total assets, net of depreciation and amortization 116,172 382,587  
Diagnostics Segment [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Lymphoseek license revenue 0 254,050  
Grant and other revenue 571,362 685,635  
Total revenue 571,362 948,485  
Cost of goods sold, excluding depreciation and amortization 0 1,489  
Research and development expenses, excluding depreciation and amortization 413,202 1,830,471  
Selling, general and administrative expenses, excluding depreciation and amortization 0 0  
Depreciation and amortization 0 0  
Income (loss) from operations 158,160 (883,475)  
Other expense 0 0  
Equity in loss of R-NAV, LLC   0  
Income tax (expense) benefit (53,254)    
Net income (loss) from continuing operations 104,906 (883,475)  
Loss from discontinued operations, net of tax (255,861) (1,004,433)  
Gain on sale of discontinued operations, net of tax 88,701,501    
Net income (loss) 88,550,546 (1,887,908)  
Payments to Acquire Property, Plant, and Equipment 0 0  
Diagnostics Segment [Member] | UNITED STATES      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization 9,692,007 4,273,762  
Diagnostics Segment [Member] | Non Us [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 8,800  
Total assets, net of depreciation and amortization 115,279 380,982  
Therapeutics Segment [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0    
Lymphoseek license revenue 0 0  
Grant and other revenue 8,668 0  
Total revenue 8,668 0  
Cost of goods sold, excluding depreciation and amortization 0 0  
Research and development expenses, excluding depreciation and amortization 292,072 241,800  
Selling, general and administrative expenses, excluding depreciation and amortization 2,521 (598)  
Depreciation and amortization 0 0  
Income (loss) from operations (285,925) (241,202)  
Other expense 0 0  
Equity in loss of R-NAV, LLC   0  
Income tax (expense) benefit 96,273    
Net income (loss) from continuing operations (189,652) (241,202)  
Loss from discontinued operations, net of tax 0 0  
Gain on sale of discontinued operations, net of tax 0    
Net income (loss) (189,652) (241,202)  
Payments to Acquire Property, Plant, and Equipment 0 0  
Therapeutics Segment [Member] | UNITED STATES      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization 897 16,515  
Therapeutics Segment [Member] | Non Us [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization 0 0  
Corporate Non Segment [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0    
Lymphoseek license revenue 0 0  
Grant and other revenue 0 0  
Total revenue 0 0  
Cost of goods sold, excluding depreciation and amortization 0 0  
Research and development expenses, excluding depreciation and amortization 0 0  
Selling, general and administrative expenses, excluding depreciation and amortization 2,943,123 2,558,758  
Depreciation and amortization 76,790 74,966  
Income (loss) from operations (3,019,913) (2,633,724)  
Other expense (1,171,109) 1,088,824  
Equity in loss of R-NAV, LLC   (12,239)  
Income tax (expense) benefit 1,411,153    
Net income (loss) from continuing operations (2,779,869) (1,557,139)  
Loss from discontinued operations, net of tax 0 0  
Gain on sale of discontinued operations, net of tax 0    
Net income (loss) (2,779,869) (1,557,139)  
Payments to Acquire Property, Plant, and Equipment 0 1,847  
Corporate Non Segment [Member] | UNITED STATES      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization 23,116,511 7,610,817  
Corporate Non Segment [Member] | Non Us [Member]      
Segment Reporting Information [Line Items]      
Lymphoseek sales revenue 0 0  
Total assets, net of depreciation and amortization $ 893 $ 1,605